Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bio-Rad Laboratories Inc lowers FY 2013 revenue guidance - Conference Call


Thursday, 7 Nov 2013 05:00pm EST 

Bio-Rad Laboratories Inc:Says FY 2013 it guided currency-neutral revenue growth to be in the 3% to 3.5% range for the base business, and 3.5% to 4% including Serotec.Says it also told that any further deterioration in Europe, or funding in the academic and government research markets, could make goals difficult to achieve.Says given year-to-date currency-neutral growth of about 2% for the base business, and 3.1% including Serotec, and combined with the continued European challenges and constrained funding environment.Says it now believe FY 2013 currency-neutral sales growth will likely remain in that same 2% to 3% range it has experienced so far this year.Says it reported revenue of $2.069 billion in fiscal 2012.FY 2013 revenue of $2.139 billion - Thomson Reuters I/B/E/S Estimates. 

Company Quote

111.3
0.95 +0.86%
20 Oct 2014